All News

@reumacia @RheumNow You are absolutely right. The point was not generally used for psoriasis ( not PsA). I was surprised my self 🤕. Here is the slide again by Dr. Armstrong , great talk by the way. Let me know if you want the handout. https://t.co/C11Gkn2jho

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
The panel addresses the question about using combination biologics and combo tsDMARDS + biologic. These combos are being studied. The panel noted combo apremilast +biologic is pretty commonly used appears to be effective and safe. #RNL2024 @rheumnow https://t.co/EeIlhJiDZU

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Nice summary of data as to why IL-17 or IL-23 are generally favoured by dermatology for psoriasis @_AprilArmstrong @RheumNow #RNL2024 https://t.co/qfAn2AHilX

Links:

Richard Conway RichardPAConway ( View Tweet)
Considerations in choosing a biologic in psoriatic disease from dermatology viewpoint @_AprilArmstrong @RheumNow #RNL2024 https://t.co/PHg0CBjTkC

Links:

Richard Conway RichardPAConway ( View Tweet)
#RNL2024 @RheumNow @_AprilArmstrong Choosing a biologic in Psoriasis TNF - great in PsA, pregnancy. Avoid in demyelinating, hep B IL-17 - robust skin, PsA (axial too). Avoid in IBD IL-23 - robust skin, PsA evidence, fewer injections https://t.co/9Xt7Nx1tKq

Links:

Eric Dein ericdeinmd ( View Tweet)
How/when to choose biologics in pts with active psoriasis from Dr April Armstrong #rnl2024

Dr. John Cush RheumNow ( View Tweet)

coronavirus,COVID,MISC,mask

Best Treatments for COVID-Related MIS-C

d Jack Cush, MD

The RECOVERY trial focused on pediatric MIS-C patients treated with immunomodulators and anti-cytokine therapy demonstrated the benefits of first-line therapy with intravenous methylprednisolone or second-line tocilizumab in children refractory to initial treatment.

Read Article
healthcare.costs_.jpg

ACR Applauds Prior Authorization Rule

d ACR

The American College of Rheumatology (ACR), on behalf of over 9,100 rheumatologists and rheumatology professional team members, applauds the Centers for Medicare and Medicaid Services (CMS) for finalizing its Advancing Interoperability and Improving Prior Authorization Processes for Medicare Adva

Read Article
IL-17 pathway as a target in giant cell arteritis - full read review of pathogenic role of IL-17 and Th17 cells, in #GCA; backed up by the phase II proof-of-principle TiTAIN study showing potential efficacy of secukinumab in GCA pts https://t.co/MThzw2joGO https://t.co/PmrJjf9C3a

Links:

Dr. John Cush RheumNow ( View Tweet)
Japanese retrospective study compared RA pts on JAK inhib vs bDMARDs (n=62 ea) having orthopedic surgery; JAKi- pts had more postoperative flares (29% v 12%, P=.01), esp if JAKi held >11d (p.04). No diff in other postop complications https://t.co/NVY1Oajdve https://t.co/fwc9KWYZ9l

Links:

Dr. John Cush RheumNow ( View Tweet)
infusion.biologic.jpg

Rituximab Efficacy in MAINRITSAN Long-Term Studies

d Jack Cush, MD

The original randomized controlled, prospective MAINRITSAN study of 115 patients (87 with granulomatosis with polyangiitis, 23 with microscopic polyangiitis, and 5 with renal-limited ANCA-associated vasculitis [AAV]) demonstrated superiority of rituximab (RTX) over azathioprine (AZA) for maintenance of remission at 22 months in ANCA-associated vasculitis patients after CYC remission induction.

Read Article
Excited to be talking at https://t.co/hposbnLVdD!! As usual, @RheumNow screen-grabbed me at an opportune moment 🤣😆 Highly recommend the conference; register live/online at the link above! https://t.co/XewJXRASi8

Links:

Mike Putman EBRheum ( View Tweet)
Excited to be talking at https://t.co/hposbnLVdD!! As usual, @RheumNow screen-grabbed me at an opportune moment 🤣😆 Highly recommend the conference; register live/online at the link above! https://t.co/XewJXRASi8

Links:

Mike Putman EBRheum ( View Tweet)
European ustekinumab (Stelara) biosimilar Uzpruvo® (AVT04) was granted marketing authorisation by European Commission & will be available in July 2024. US FDA approved Wezlana (ustekinumab-auub) in 11/2023. https://t.co/Wv2Z7P5xAu https://t.co/PdGEUpyRU6

Links:

Dr. John Cush RheumNow ( View Tweet)
Real-world data of 5070 RA pts (1816 Rx w/ b/tsDMARDs) showed the use of tsDMARD considerably increased from 2012 to 2021. All b/tsDMARDs pts improved Dz activity & function/ 10 yr effiicacy best for IL6Ri in switch pts and ABA in bNAIVE pts https://t.co/h9j8Pk03if https://t.co/gC7Wloujm0

Links:

Dr. John Cush RheumNow ( View Tweet)
Jo1.gottrons.jpg

Drug-Induced Dermatomyositis

d Jack Cush, MD

A JAMA Dermatology systematic review of drug-induced dermatomyositis (DM) found the most commonly implicated agents include hydroxyurea, immune checkpoint inhibitors, statins and lipid-lowering agents, penicillamine, and tumor necrosis factor inhibitors.

Read Article
2023, Year, Wordle

2023 Rheumatology Year in Review

d Jack Cush, MD

Here is my top 10 list (in no particular order) of 2023 advances, game-changers, and developments that changed, or will soon change, rheumatologic practices.

Read Article
Experience the Future of Rheumatology at RheumNow Live 2024, just three weeks away! Don't miss out – secure your spot today for an unforgettable journey into the latest advancements and insights. https://t.co/HN8ErCpSMb https://t.co/kCYD7Hbhxx

Links:

Dr. John Cush RheumNow ( View Tweet)
Anti-TNF mAbs, JAKi & anti-IL17 Rx appear protective against anterior Uveitis in AxSpA pts. Network Metanalysis of 44 trials, AU IR -TNF mAb: 4.1, ETN: 5.4, IL17i: 2.8, JAKi: 1.5, & placebo: 10.8. AU risk: TNFi < JAKi < IL-17i < ETN << PBO https://t.co/3zIcvuIaBV https://t.co/UseZ6t00EB

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

New Year's Resolutions (1.5.2024)

d Jack Cush, MD

Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.